Clinuvel Pharmaceuticals Ltd
XMUN:UR9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Clinuvel Pharmaceuticals Ltd
XMUN:UR9
|
AU |
|
S
|
SillaJen Inc
KOSDAQ:215600
|
KR |
|
Embelton Ltd
ASX:EMB
|
AU |
|
I
|
Investec Property Fund Ltd
JSE:IPF
|
ZA |
|
P
|
Path Investments PLC
LSE:PATH
|
UK |
|
Medmix Ltd
SIX:MEDX
|
CH |
|
N
|
NextCure Inc
F:2US
|
US |
|
R
|
RAM Essential Services Property Fund
ASX:REP
|
AU |
|
audius SE
F:3IT
|
DE |
|
D
|
Digital Media Solutions Inc
OTC:DMSL
|
US |
Wall St Price Targets
UR9 Price Targets Summary
Clinuvel Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for UR9 is 14.687 EUR with a low forecast of 7.864 EUR and a high forecast of 25.657 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is UR9's stock price target?
Price Target
14.687
EUR
According to Wall Street analysts, the average 1-year price target for UR9 is 14.687 EUR with a low forecast of 7.864 EUR and a high forecast of 25.657 EUR.
What is the Revenue forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 39%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
The compound annual growth rate for Gross Profit over the next 8 years is 8%.
What is the Operating Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
9%
The compound annual growth rate for Operating Income over the next 8 years is 9%.
What is the Pre-Tax Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
20%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 20%.
What is the Net Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
11%
The compound annual growth rate for Net Income over the next 8 years is 11%.
